Intellectual Property

Enlyton has a diverse intellectual property portfolio, with issued U.S. and foreign patents, and pending U.S. and foreign patent applications. A portion of this portfolio addresses a family of monoclonal antibodies for which Enlyton has secured a worldwide exclusive license from the National Institutes of Health for multiple fields of use. Collectively, Enlyton’s intellectual property addresses novel molecular targeting agents for use in:

•  cancer imaging
•  detection and surgical removal of known and occult cancerous tissue in real-time
•  surgical margin assessment
•  fluorescence-based cancer detection
•  cancer diagnostics and prognostication
•  targeted drug delivery